Terragen Launches New Ruminant Probiotics, Advances US Patent and Global Trials
Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.
- Launch of Terragen Probiotic for Ruminants and Terragen Probiotic Ultra
- Ellinbank 3 methane mitigation trial underway with interim results expected June 2025
- Canadian beef feedlot trial pending regulatory approval, marking entry into North American markets
- US patent allowance received for Terragen Probiotic for Ruminants, expected issuance June 2025
- Strong financial position with $5.8 million cash reserves post equity raising
Product Launch and Market Entry
Terragen Holdings Limited has marked a significant milestone with the launch of its new dry format products, Terragen Probiotic for Ruminants and Terragen Probiotic Ultra for Ruminants. These products, now available online and through major Australian agri-retailers, are supported by a comprehensive marketing campaign and in-house veterinary expertise. The dry formulation enhances product shelf life and ease of integration into feed rations, reflecting Terragen's commitment to innovation in livestock health.
Ongoing Research and Trials
Research remains a cornerstone of Terragen's strategy. The Ellinbank 3 trial, conducted at Agriculture Victoria’s Ellinbank SmartFarm, is evaluating the probiotic's effectiveness in reducing methane emissions from dairy cows. This trial, involving 70 lactating cows over 60 days, will provide critical data on methane mitigation and animal productivity, with interim results due in June 2025.
Internationally, Terragen is advancing its presence with a Canadian beef feedlot trial pending approval from the Canadian Food Inspection Agency. This two-phase study, in collaboration with Agriculture and Agri-Food Canada and other partners, aims to validate the probiotic’s benefits under North American feedlot conditions, a market with millions of cattle on feed.
Expansion into Companion Animal Market and Crop Enhancements
Terragen has also initiated a canine safety and palatability trial with Invetus, Australia’s largest veterinary research organisation, signaling its entry into the companion animal sector. Meanwhile, encouraging results from Great Land Plus® trials on canola and maize demonstrate yield improvements and potential reductions in synthetic fertiliser use, reinforcing Terragen’s environmental and agricultural impact.
Regulatory Progress and Intellectual Property
On the regulatory front, Terragen has completed phase two of its global market access strategy for the US and Canada, with final submissions anticipated soon. Notably, the United States Patent and Trademark Office has issued a Notice of Allowance for Terragen Probiotic for Ruminants, with patent issuance expected in June 2025. This intellectual property milestone strengthens Terragen’s competitive position in key international markets.
Financial Position and Outlook
Financially, Terragen ended the quarter with $5.8 million in cash reserves, bolstered by a recent equity raising that secured $4.76 million in gross proceeds. Investments during the quarter included procurement of raw materials for product manufacturing and payments related to successful trial completions. The company’s cash flow reflects ongoing commitment to research, development, and commercialisation activities.
Terragen’s integrated approach, combining scientific validation, product innovation, and strategic market access, positions it well to capitalise on growing demand for sustainable agricultural solutions domestically and internationally.
Bottom Line?
With key trials progressing and patent protections secured, Terragen is poised for accelerated global growth in sustainable agriculture.
Questions in the middle?
- Will interim results from the Ellinbank 3 trial confirm methane reduction efficacy to support regulatory approvals?
- How soon can Terragen expect full commercial approval and market penetration in North America following the Canadian trial?
- What is the potential commercial impact of Terragen’s entry into the companion animal probiotic market?
